Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alto Neuroscience (ANRO) Research & Development (2023 - 2026)

Alto Neuroscience has reported Research & Development over the past 4 years, most recently at $20.3 million for Q1 2026.

  • Quarterly results put Research & Development at $20.3 million for Q1 2026, up 103.47% from a year ago — trailing twelve months through Mar 2026 was $55.9 million (up 18.97% YoY), and the annual figure for FY2025 was $45.6 million, down 2.93%.
  • Research & Development reached $20.3 million in Q1 2026 per ANRO's latest filing, up from $12.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $20.3 million in Q1 2026 and bottomed at -$20.4 million in Q4 2023.
  • Median Research & Development over the past 4 years was $10.5 million (2025), compared with a mean of $8.7 million.
  • The largest annual shift saw Research & Development surged 152.82% in 2024 before it decreased 19.41% in 2025.
  • Over 4 years, Research & Development stood at -$20.4 million in 2023, then soared by 152.82% to $10.8 million in 2024, then rose by 11.07% to $12.0 million in 2025, then soared by 69.17% to $20.3 million in 2026.
  • Business Quant data shows Research & Development for ANRO at $20.3 million in Q1 2026, $12.0 million in Q4 2025, and $10.5 million in Q3 2025.